Volume 73, Issue 5, Pages (May 2018)

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 61, Issue 5, Pages (May 2012)

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 3, Pages (March 2013)

Pascal Rischmann European Urology Supplements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 70, Issue 1, Pages (July 2016)

Testosterone Therapy in Men With Prostate Cancer

Volume 57, Issue 1, Pages (January 2010)

Volume 53, Issue 4, Pages (April 2008)

Volume 59, Issue 3, Pages (March 2011)

Contemporary Management of the Painful Bladder: A Systematic Review

Volume 65, Issue 4, Pages (April 2014)

Volume 61, Issue 1, Pages (January 2012)

Volume 54, Issue 6, Pages (December 2008)

Volume 61, Issue 5, Pages (May 2012)

Volume 54, Issue 3, Pages (September 2008)

Volume 53, Issue 5, Pages (May 2008)

Volume 66, Issue 3, Pages (September 2014)

Volume 60, Issue 1, Pages (July 2011)

Volume 60, Issue 6, Pages (December 2011)

Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Let the Games Begin (with EAU Approval)

Ashish M. Kamat, Sima Porten European Urology

Volume 63, Issue 4, Pages e53-e56 (April 2013)

What is New in Bladder Cancer Diagnosis and Management?

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 47, Issue 2, Pages (February 2005)

Volume 55, Issue 6, Pages (June 2009)

Volume 54, Issue 4, Pages (October 2008)

Volume 66, Issue 4, Pages (October 2014)

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 67, Issue 3, Pages (March 2015)

Volume 70, Issue 1, Pages (July 2016)

Volume 66, Issue 6, Pages (December 2014)

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

Stephen B. Williams, Ashish M

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 67, Issue 6, Pages (June 2015)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 70, Issue 2, Pages (August 2016)

European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Volume 68, Issue 4, Pages (October 2015)

Volume 50, Issue 5, Pages (November 2006)

Volume 50, Issue 3, Pages (September 2006)

Volume 55, Issue 3, Pages (March 2009)

Volume 51, Issue 1, Pages (January 2007)

Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations Raj Persad, Donald Lamm,

Volume 54, Issue 4, Pages (October 2008)

Volume 53, Issue 5, Pages (May 2008)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Economic Burden of Bladder Cancer Across the European Union

Volume 52, Issue 4, Pages (October 2007)

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events J. Alfred Witjes, Joan Palou, Mark.

Systematic Review of Complications of Prostate Biopsy

Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guérin Gregory E.J. Harding,

Volume 51, Issue 5, Pages (May 2007)

Maximilian Burger, Ashish M. Kamat, David McConkey

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Volume 73, Issue 5, Pages 738-748 (May 2018) Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review Ashish M. Kamat, Roger Li, Michael A. O’Donnell, Peter C. Black, Morgan Roupret, James W. Catto, Eva Comperat, Molly A. Ingersoll, Wim P. Witjes, David J. McConkey, J. Alfred Witjes European Urology Volume 73, Issue 5, Pages 738-748 (May 2018) DOI: 10.1016/j.eururo.2017.10.003 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 CyPRIT Nomogram for calculating the risk of recurrence using changes in urinary cytokine levels from immediately before to 4h after instillation of BCG at the last dose of induction (ie, at 6 wk). BCG=bacillus Calmette-Guérin; CyPRIT=Cytokine Panel for Response to Intravesical Therapy; IFN=interferon; IL=interleukin; TNF=tumor necrosis factor. Adapted from Kamat et al [61]. European Urology 2018 73, 738-748DOI: (10.1016/j.eururo.2017.10.003) Copyright © 2017 European Association of Urology Terms and Conditions